MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Quotient Limited DPO Ratio 2011-2026 | QTNT
Annual DPO Ratio Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 86.2 | 99 | 126 | 190 | 363 | 275 | 271 | 232 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 363 | 86.2 | 205 |
Quarterly DPO Ratio Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 76.7 | 13.6 | 16.8 | - | 50.3 | 26.2 | 43.6 | 90.3 | 108 | 101 | 109 | 77 | 75 | 93.5 | 130 | 89.3 | 61.5 | 87.4 | 108 | - | 369 | 288 | 336 | - | 309 | 90.6 | 124 | - | 436 | 134 | 151 | - | 218 | 74.1 | 109 | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 436 | 13.6 | 133 |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
RadNet
RDNT
|
23.5 | $ 56.78 | -4.44 % | $ 4.27 B |  USA |
 |
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Soleno Therapeutics
SLNO
|
1.44 K | $ 30.52 | -4.12 % | $ 1.55 B | USA |
 |
Enzo Biochem
ENZ
|
52.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
49.2 | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Neuronetics
STIM
|
51.8 | $ 1.4 | 4.89 % | $ 92.3 M | USA |
 |
Sotera Health Company
SHC
|
46.9 | $ 13.26 | -2.1 % | $ 3.77 B | USA |
 |
Heska Corporation
HSKA
|
39.7 | - | - | $ 1.31 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M |  Britain |
 |
BioNano Genomics
BNGO
|
149 | $ 1.16 | 0.87 % | $ 6.32 M | USA |
 |
Trinity Biotech plc
TRIB
|
163 | $ 0.6 | -2.18 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
12.5 | - | - | $ 2.68 B | USA |
 |
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
112 | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
125 | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | China |
 |
HTG Molecular Diagnostics
HTGM
|
112 | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
52 | $ 23.99 | -2.87 % | $ 666 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
24.5 | $ 158.77 | -3.85 % | $ 7.87 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
14.7 | $ 195.86 | -1.16 % | $ 21.7 B | USA |
 |
Organovo Holdings
ONVO
|
82.9 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
95 | - | -16.95 % | $ 1.54 M | USA |
 |
DarioHealth Corp.
DRIO
|
112 | $ 8.45 | - | $ 33.7 M |  Israel |
 |
Waters Corporation
WAT
|
102 | $ 290.62 | -3.31 % | $ 17.3 B | USA |
 |
Biocept
BIOC
|
56.3 | - | -13.05 % | $ 7.29 M | USA |
 |
PerkinElmer
PKI
|
57.9 | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
69 | - | - | $ 21.2 M | USA |
 |
Interpace Biosciences
IDXG
|
34.4 | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
IQVIA Holdings
IQV
|
126 | $ 164.81 | -2.71 % | $ 28.3 B | USA |
 |
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
50 | - | - | $ 10.6 B |  Niderland |
 |
Neogen Corporation
NEOG
|
62.7 | $ 8.79 | -3.93 % | $ 1.91 B | USA |
 |
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M | USA |
 |
Personalis
PSNL
|
67.3 | $ 6.41 | -12.43 % | $ 380 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
31.5 | $ 266.15 | -0.83 % | $ 22.1 B | USA |
 |
Senseonics Holdings
SENS
|
68 | $ 6.45 | -1.68 % | $ 269 M | USA |
 |
Psychemedics Corporation
PMD
|
16 | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
53 | $ 25.64 | -5.75 % | $ 33.3 M | USA |
 |
CareDx, Inc
CDNA
|
44.2 | $ 16.82 | -3.72 % | $ 896 M | USA |
 |
Syneos Health
SYNH
|
10.1 | - | - | $ 4.46 B | USA |
 |
Renalytix AI plc
RNLX
|
122 | - | 5.66 % | $ 22.7 M | Britain |